NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Forecast, Price & News $1.36 +0.03 (+2.26%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.28▼$1.3650-Day Range$1.20▼$1.7852-Week Range$1.12▼$8.87Volume2.23 million shsAverage Volume3.14 million shsMarket Capitalization$128.81 millionP/E RatioN/ADividend YieldN/APrice Target$11.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Esperion Therapeutics MarketRank™ ForecastAnalyst RatingHold2.22 Rating ScoreUpside/Downside721.1% Upside$11.17 Price TargetShort InterestBearish15.63% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment0.13Based on 5 Articles This WeekInsider TradingSelling Shares$74,613 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.17) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector145th out of 983 stocksPharmaceutical Preparations Industry59th out of 486 stocks 4.1 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 4 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.17, Esperion Therapeutics has a forecasted upside of 721.1% from its current price of $1.36.Amount of Analyst CoverageEsperion Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.63% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 1.7 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 15 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold 97.76% more of their company's stock than they have bought. Specifically, they have bought $37,729.00 in company stock and sold $74,613.00 in company stock.Percentage Held by InsidersOnly 0.60% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions85.87% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($2.17) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Esperion Therapeutics (NASDAQ:ESPR) StockEsperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.Read More Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesJune 1, 2023 | msn.comHC Wainwright & Co. Reiterates Esperion Therapeutics (ESPR) Buy RecommendationJune 1, 2023 | markets.businessinsider.comAnalyst Ratings for Esperion TherapeuticsJune 2, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 1, 2023 | finance.yahoo.comEsperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) TabletMay 25, 2023 | finance.yahoo.comEsperion Announces Adjournment of 2023 Annual Meeting of StockholdersMay 24, 2023 | finance.yahoo.comEsperion to Participate in Jefferies Healthcare ConferenceMay 21, 2023 | fool.comEsperion Therapeutics (NASDAQ: ESPR)May 13, 2023 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) CEO Purchases $25,200.00 in StockJune 2, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 13, 2023 | americanbankingnews.comFY2024 Earnings Forecast for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Issued By HC WainwrightMay 13, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Esperion Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:ESPR)May 12, 2023 | markets.businessinsider.comBank of America Securities Sticks to Their Sell Rating for Esperion (ESPR)May 11, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Esperion (ESPR), Guardant Health (GH)May 11, 2023 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Hold" from AnalystsMay 10, 2023 | finance.yahoo.comEsperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock UpMay 9, 2023 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Reports First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comEsperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9May 1, 2023 | finance.yahoo.comEsperion to Participate in JMP Securities Life Sciences ConferenceApril 27, 2023 | finance.yahoo.comEsperion to Participate in Bank of America Securities 2023 Health Care ConferenceApril 25, 2023 | msn.comUnusual Put Option Trade in Esperion Therapeutics (ESPR) Worth $30.00KApril 25, 2023 | finance.yahoo.comEsperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 25, 2023 | finance.yahoo.comEsperion to Report First Quarter 2023 Financial Results May 9, 2023April 19, 2023 | finance.yahoo.comEsperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLCApril 19, 2023 | msn.comNeedham Reiterates Esperion Therapeutics (ESPR) Buy RecommendationApril 14, 2023 | americanbankingnews.comBrokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $11.17April 9, 2023 | americanbankingnews.comFY2023 EPS Estimates for Esperion Therapeutics, Inc. Decreased by Zacks Research (NASDAQ:ESPR)April 3, 2023 | finance.yahoo.comEsperion to Participate in Needham 22nd Annual Virtual Healthcare ConferenceSee More Headlines ESPR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Company Calendar Last Earnings5/09/2023Today6/02/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees218Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.17 High Stock Price Forecast$22.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+739.6%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-233,660,000.00 Net Margins-294.74% Pretax Margin-294.74% Return on EquityN/A Return on Assets-85.49% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.21 Sales & Book Value Annual Sales$75.47 million Price / Sales1.67 Cash FlowN/A Price / Cash FlowN/A Book Value($3.48) per share Price / Book-0.38Miscellaneous Outstanding Shares94,710,000Free Float94,145,000Market Cap$125.96 million OptionableOptionable Beta0.15 Key ExecutivesSheldon L. KoenigPresident, Chief Executive Officer & DirectorBenjamin HalladayChief Financial OfficerKen FiorelliChief Technical Operations OfficerJoAnne Micale FoodyChief Medical OfficerWilliam J. SasielaSenior Vice President-Clinical DevelopmentKey CompetitorsOrganigramNASDAQ:OGICelularityNASDAQ:CELUIncannex HealthcareNASDAQ:IXHLGalera TherapeuticsNASDAQ:GRTXMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 189,051 shares on 5/18/2023Ownership: 0.197%New York State Common Retirement FundSold 20,353 shares on 5/18/2023Ownership: 0.026%Eric WarrenSold 219 sharesTotal: $354.78 ($1.62/share)Jane Street Group LLCBought 8,400 shares on 5/16/2023Ownership: 0.000%Susquehanna Fundamental Investments LLCSold 28,907 shares on 5/16/2023Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions ESPR Stock - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price forecast for 2023? 9 equities research analysts have issued 12 month price targets for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $1.50 to $22.00. On average, they predict the company's share price to reach $11.17 in the next twelve months. This suggests a possible upside of 739.6% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2023? Esperion Therapeutics' stock was trading at $6.23 on January 1st, 2023. Since then, ESPR shares have decreased by 78.7% and is now trading at $1.33. View the best growth stocks for 2023 here. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.14. The biopharmaceutical company had revenue of $24.30 million for the quarter, compared to the consensus estimate of $21.97 million. The business's revenue for the quarter was up 29.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.93) EPS. What ETFs hold Esperion Therapeutics' stock? ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (17.44%), Balyasny Asset Management L.P. (5.04%), Meditor Group Ltd (4.94%), Armistice Capital LLC (3.88%), Platinum Investment Management Ltd. (3.37%) and State Street Corp (2.01%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $1.33. How much money does Esperion Therapeutics make? Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $125.96 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. How many employees does Esperion Therapeutics have? The company employs 218 workers across the globe. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com. This page (NASDAQ:ESPR) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.